

A2
cont'd
dimensional structure of LTA₄ hydrolase is essentially as disclosed in Table 9 by the parameters defining atom 1- atom 4876, or a functionally equivalent part, derivative or conformational analogue of such a complex.

A3
11. (Amended) Use of the parameters of a protein according to claim 1, a compound according to claim 6 in drug design, such as in molecular modeling, direct structure-based design and/or combinatorial chemistry.

13. (Amended) Use according to claim 11, wherein said drug is for the treatment and/or prevention of disorders involving acute and chronic inflammatory and/or allergic symptoms, said disorder being selected from the group consisting of arthritis, inflammatory bowel disease (IBD), psoriasis, chronic obstructive pulmonary disease (COPD), and acquired immune deficiency syndrome (AIDS).

14. (Amended) Use according to claim 11, wherein said drug is for the treatment and/or prevention of proliferative disorders, such as neoplasias and/or cancer.

15. (Amended) Use according to claim 11, wherein said drug is for the treatment and/or prevention of disorders caused by the lethal factor of *Bacillus anthracis*, e.g. anthrax.

A5
18. (Amended) A method according to claim 16, wherein an enzymatic inhibitor complementary to the amino acids defined in claim 3 is screened for.

19. (Amended) An analogue obtainable by the method of claim 16.

A6
25. (Amended) A compound obtainable by the method according to claim 21.

28. (Amended) A process for the purification of a protein according to claim 1 or obtained according to claim 26, which purification includes hydroxyapatite-based chromatography and a subsequent anion exchange chromatography.

29. 30. (Amended) A protein obtained by the method according to claim 26.

31. 35. (Amended) A protein according to any one of claims 6, 25, 30 or 31 for use as a medicament.

Please cancel claims 36-38.